Glucotrack to Present at TechBio Showcase™ 2025
Glucotrack (Nasdaq: GCTK), a medical technology company specializing in diabetes care technologies, has announced its participation in the upcoming TechBio Showcase™ 2025. The company's President and CEO, Paul V. Goode, will deliver a corporate update focusing on their Continuous Blood Glucose Monitor (CBGM) technology.
The presentation is scheduled for Tuesday, January 14, at 9:30am PT in the Yosemite C track. TechBio Showcase, part of Biotech Showcase™ 2025, is organized by Demy-Colton and EBD Group. This investor conference serves as a networking platform for executives and investors, promoting geographical investment and partnership opportunities in therapeutic development.
Glucotrack (Nasdaq: GCTK), un'azienda di tecnologia medica specializzata nelle tecnologie per la cura del diabete, ha annunciato la sua partecipazione al prossimo TechBio Showcase™ 2025. Il Presidente e CEO della compagnia, Paul V. Goode, presenterà un aggiornamento aziendale incentrato sulla loro tecnologia Continuous Blood Glucose Monitor (CBGM).
La presentazione è prevista per martedì 14 gennaio, alle 9:30 ora del Pacifico, nella track Yosemite C. Il TechBio Showcase, parte del Biotech Showcase™ 2025, è organizzato da Demy-Colton e EBD Group. Questa conferenza per investitori funge da piattaforma di networking per dirigenti e investitori, promuovendo opportunità di investimento e partnership geografiche nello sviluppo terapeutico.
Glucotrack (Nasdaq: GCTK), una empresa de tecnología médica especializada en tecnologías para el cuidado de la diabetes, ha anunciado su participación en el próximo TechBio Showcase™ 2025. El Presidente y CEO de la compañía, Paul V. Goode, ofrecerá una actualización corporativa centrada en su tecnología de Monitoreo Continuo de Glucosa en Sangre (CBGM).
La presentación está programada para el martes 14 de enero a las 9:30 a.m. PT en la pista Yosemite C. El TechBio Showcase, parte del Biotech Showcase™ 2025, es organizado por Demy-Colton y EBD Group. Esta conferencia para inversores sirve como una plataforma de networking para ejecutivos e inversores, promoviendo oportunidades de inversión y asociación geográfica en el desarrollo terapéutico.
글루코트랙 (Nasdaq: GCTK), 당뇨 관리 기술에 특화된 의료 기술 기업이 다가오는 테크바이오 쇼케이스™ 2025에 참가한다고 발표했습니다. 회사의 회장 겸 CEO인 Paul V. Goode는 지속 혈당 모니터(CBGM) 기술에 대한 기업 업데이트를 제공할 예정입니다.
발표는 1월 14일 화요일, 태평양 표준시로 오전 9시 30분에 요세미티 C 트랙에서 진행됩니다. TechBio Showcase는 Biotech Showcase™ 2025의 일환으로, Demy-Colton과 EBD Group이 주최합니다. 이 투자자 회의는 임원과 투자자 간의 네트워킹 플랫폼으로 기능하며, 치료 개발에 있어 지리적 투자와 파트너십 기회를 촉진합니다.
Glucotrack (Nasdaq: GCTK), une entreprise de technologie médicale spécialisée dans les technologies de soin du diabète, a annoncé sa participation au prochain TechBio Showcase™ 2025. Le Président et CEO de l'entreprise, Paul V. Goode, présentera une mise à jour de l'entreprise axée sur leur technologie de Moniteur de Glucose Sanguin Continu (CBGM).
La présentation est prévue pour le mardi 14 janvier à 9h30 PT dans la piste Yosemite C. Le TechBio Showcase, qui fait partie du Biotech Showcase™ 2025, est organisé par Demy-Colton et EBD Group. Cette conférence pour investisseurs sert de plateforme de réseautage pour les dirigeants et investisseurs, favorisant des opportunités d'investissement et de partenariat géographiques dans le développement thérapeutique.
Glucotrack (Nasdaq: GCTK), ein Medizintechnikunternehmen, das sich auf Technologien zur Diabetesversorgung spezialisiert hat, hat seine Teilnahme an der bevorstehenden TechBio Showcase™ 2025 angekündigt. Der Präsident und CEO des Unternehmens, Paul V. Goode, wird ein Unternehmensupdate zu ihrer Continuous Blood Glucose Monitor (CBGM)-Technologie präsentieren.
Die Präsentation ist für Dienstag, den 14. Januar, um 9:30 Uhr PT in der Yosemite C-Track geplant. Die TechBio Showcase, die Teil des Biotech Showcase™ 2025 ist, wird von Demy-Colton und EBD Group organisiert. Diese Investorenkonferenz dient als Networking-Plattform für Führungskräfte und Investoren und fördert geografische Investitions- und Partnerschaftsmöglichkeiten in der therapeutischen Entwicklung.
- None.
- None.
Presentation to feature an update on the Company’s novel continuous blood glucose monitor for patients with diabetes
RUTHERFORD, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it is presenting at TechBio Showcase, part of Biotech Showcase™ 2025. Paul V. Goode, President and Chief Executive Officer, will give a corporate update on the Company’s Continuous Blood Glucose Monitor (CBGM).
Date: Tuesday, January 14
Time: 9:30am PT
Track: Yosemite C (Ballroom Level)
TechBio Showcase, as part of Biotech Showcase, is produced by Demy-Colton and EBD Group, and is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters broad geographical investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks. Register now to meet one-to-one: biotechshowcase.com.
For more information about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
About TechBio SHOWCASE
TechBio Showcase is part of Biotech Showcase, which is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 17th year, Biotech Showcase is a well-established, highly respected conference featuring multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 28, 2024.
Contacts:
Investor Relations:
investors@glucotrack.com
Lisa Wilson
In-Site Communications
T: 917-543-9932
E: lwilson@insitecony.com
Media:
GlucotrackPR@icrinc.com
FAQ
When and where is Glucotrack (GCTK) presenting at TechBio Showcase 2025?
What will Glucotrack (GCTK) present at TechBio Showcase 2025?
What is the purpose of TechBio Showcase where GCTK is presenting?
Who organizes the TechBio Showcase where Glucotrack (GCTK) is presenting?
